EWTX
Edgewise Therapeutics, Inc. · Healthcare
31.89
2.86%(-0.94)
Market OpenLast Updated: — ET
52W L: $10.7752W H: $34.00
$31.82
CHG+4.30 (+15.63%)
H$34.00
L$26.38
VOL14M
EWTX (1h)
Edgewise Therapeutics, Inc. · Healthcare
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shares hit a new 52-week high on Tuesday. The stock traded as high as $34.00 and last traded at $32.83, with a volume of 577238 shares traded. The stock had previously closed at $33.33. Wall Street Analysts Forecast Growth Several equities research analysts have recently weighed
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) have been given an average rating of "Moderate Buy" by the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation
SG Americas Securities LLC raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 797.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,723 shares of the company's stock after acquiring an additional 78,842 shares during the period.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) CMO Joanne Donovan sold 28,662 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $32.31, for a total value of $926,069.22. The sale was disclosed in a document filed with the Securities and
BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
She raised her price target by $11 per share. In her view, the company's No.
Fox Jonathan C
director
339 SH @ $0.00
2026-04-01
Donovan Joanne M.
officer: CMO
28,662 SH @ $7.08
2026-04-01
Donovan Joanne M.
officer: CMO
28,662 SH @ $7.08
2026-04-01
Donovan Joanne M.
officer: CMO
28,662 SH @ $32.31
2026-04-01
Donovan Joanne M.
officer: CMO
21,338 SH @ $7.08
2026-03-31
Donovan Joanne M.
officer: CMO
21,338 SH @ $7.08
2026-03-31
Donovan Joanne M.
officer: CMO
21,338 SH @ $32.12
2026-03-31
Donovan Joanne M.
officer: CMO
9,623 SH @ $30.98
2026-03-27